UY31723A - USE OF RECEIVER ANTAGONISTS 2 ACTIVADOCON PROTEASA - Google Patents

USE OF RECEIVER ANTAGONISTS 2 ACTIVADOCON PROTEASA

Info

Publication number
UY31723A
UY31723A UY0001031723A UY31723A UY31723A UY 31723 A UY31723 A UY 31723A UY 0001031723 A UY0001031723 A UY 0001031723A UY 31723 A UY31723 A UY 31723A UY 31723 A UY31723 A UY 31723A
Authority
UY
Uruguay
Prior art keywords
pain
par2
activadocon
proteasa
antibody
Prior art date
Application number
UY0001031723A
Other languages
Spanish (es)
Inventor
Lynn Macdonald
Richard Torres
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY31723A publication Critical patent/UY31723A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un antagonisa del receptor 2 activado con proteasa (PAR2) para el tratamiento del dolor que incluye el dolor postoperatorio en una incisión, el dolor neuropático, el dolor por fractura, el dolor por fractura osteoporótica, el dolor por cáncer de hueso o el dolor articular por gota; el dolor inflamatorio asociado con el síndrome de colon irritable; y la inflamación relacionada con la artritis reumatoide o la osteoartritis. Preferentemente, el antagonista de PAR2 es un anticuerpo anti-PAR2 humano o un fragmento de un anticuerpo que se une al antígeno.Use of a protease activated receptor 2 (PAR2) antagonist for the treatment of pain that includes postoperative pain in an incision, neuropathic pain, fracture pain, osteoporotic fracture pain, bone cancer pain or joint pain from gout; inflammatory pain associated with irritable bowel syndrome; and inflammation related to rheumatoid arthritis or osteoarthritis. Preferably, the PAR2 antagonist is a human anti-PAR2 antibody or a fragment of an antibody that binds to the antigen.

UY0001031723A 2008-03-19 2009-03-19 USE OF RECEIVER ANTAGONISTS 2 ACTIVADOCON PROTEASA UY31723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790808P 2008-03-19 2008-03-19
US11915508P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
UY31723A true UY31723A (en) 2009-11-10

Family

ID=40718925

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031723A UY31723A (en) 2008-03-19 2009-03-19 USE OF RECEIVER ANTAGONISTS 2 ACTIVADOCON PROTEASA

Country Status (6)

Country Link
AR (1) AR070911A1 (en)
CL (1) CL2009000660A1 (en)
PE (1) PE20091693A1 (en)
TW (1) TW201002345A (en)
UY (1) UY31723A (en)
WO (1) WO2009117481A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (en) 2009-09-09 2018-03-08 Regeneron Pharma High affinity human antibodies to human protease-activated receptor-2
WO2013064583A1 (en) 2011-11-04 2013-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
CA3024719A1 (en) * 2016-05-20 2017-11-23 Takeda Pharmaceutical Company Limited Treatment of pain
US20190201454A1 (en) * 2016-06-23 2019-07-04 Mayo Foundation For Medical Education And Research Par2 modulation to alter myelination
TWI788332B (en) * 2017-03-16 2023-01-01 英商梅迪繆思有限公司 Anti-par2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
NZ334998A (en) * 1995-01-25 2000-11-24 Cor Therapeutics Inc Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
WO2005123193A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain

Also Published As

Publication number Publication date
AR070911A1 (en) 2010-05-12
WO2009117481A1 (en) 2009-09-24
PE20091693A1 (en) 2009-11-16
TW201002345A (en) 2010-01-16
CL2009000660A1 (en) 2010-04-16

Similar Documents

Publication Publication Date Title
UY31723A (en) USE OF RECEIVER ANTAGONISTS 2 ACTIVADOCON PROTEASA
PE20140633A1 (en) NEUTRALIZING ANTIBODIES ANTI-CCL20
AR074360A1 (en) MONOCLONAL ANTIBODY OR FRAGMENT OF UNION TO ANTIGEN OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
CL2017001379A1 (en) Anti-cgrp compositions and their use (divisional application 3336-2013)
CY1118691T1 (en) COMPOSITIONS AND METHODS OF USE FOR STRENGTHENING ANTIBODIES
CL2011000975A1 (en) Antibody or fragment thereof that binds to at least one toll 3 receptor amino acid residue (tlr3); pharmaceutical composition that includes it; its use to treat an inflammatory condition.
PE20080035A1 (en) HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR TYPE KINASE-1
CY1119789T1 (en) CGRP ANTIBODIES
AR073072A1 (en) HUMAN ANTIBODIES FOR THE BINDING OF THE HUMAN NF-KB RECEIVER ACTIVATOR (RANKL)
CY1121167T1 (en) IMPROVED ANTIBODIES AGAINST HUMAN FRACTALKIN AND THEIR USES
PE20190622A1 (en) GLUCOCORTICOID AND IMMUNOCONJUGATE RECEPTOR AGONIST OF THE SAME
PE20091713A1 (en) INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS
CL2012002433A1 (en) Isolated antibody or immunoreactive fragment thereof comprising a variable domain that specifically binds to an extracellular domain of the b7-h3 receptor; nucleic acid encoding it; hybridoma that secretes it; double affinity redirection reagent (dart) comprising it; pharmaceutical composition comprising it; and its use to treat cancer.
CL2007001840A1 (en) Neutralizing antibody that binds to human interleukin 17 (il-17); DNA sequence encoding it; vector and host cell that comprise it; production process; pharmaceutical preparation that includes it; and its use for the treatment or prophylaxis of pathologies mediated by il-17.
AR073140A1 (en) ANTI-IL-23R ANTIBODIES DESIGNED
PE20142243A1 (en) ANTIBODIES THAT BIND OX40 AND ITS USES
CL2008002444A1 (en) Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
PE20120429A1 (en) MYOSTATIN BINDING PROTEINS
PE20141045A1 (en) BCMA BINDING PROTEINS (CD269 / TNFRSF17)
CL2008001742A1 (en) Monoclonal antibody that recognizes a conformational epitope and binds to polymeric soluble amyloid peptides and oligomeric amyloid peptides; polynucleotide that encodes it; composition that includes it; and its use to treat diseases associated with amyloid proteins.
CL2012001540A1 (en) Antibodies or antigen-binding fragment that antagonizes prolactin receptor-mediated signaling; nucleic acid sequence; pharmaceutical composition comprising the antibody; use of the antibody for combined treatment with estrogen and progestin.
CL2011000269A1 (en) Antibody or fragment thereof that binds to cd127; and method of treating autoimmune disease or an inflammatory disorder in humans, which comprises administering an antagonist of at least one of the expansion of th17 mediated by the il-7 receptor and the survival of th17 mediated by the il-7 receptor.
CL2008001467A1 (en) Cylcr4 antagonist cylindrical peptides cycled by lactams: pharmaceutical composition comprising them; and its use to treat rheumatic arthritis, pulmonary fibrosis, hiv infection or cancer.
MX2010003574A (en) Il-23 antibodies.
MY145810A (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130122